Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation

@inproceedings{Lee2017SurvivalEA,
  title={Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation},
  author={Hye Won Lee and Hyun Soo Kim and Seung Up Kim and Do Young Kim and Beom Kyung Kim and Jun Yong Park and Sang Hoon Ahn and Mi Young Jeon and Ja Yoon Heo and Soo Young Park and Yu Rim Lee and Sun Kyung Jang and Su Hyun Lee and Se Young Jang and Won Young Tak and Kwang Hyub Han},
  booktitle={Gut and liver},
  year={2017}
}
Background/Aims Limited information is available regarding patient survival after sorafenib discontinuation in patients with hepatocellular carcinoma (HCC). Thus, we developed and validated a novel survival prediction model. Methods Clinical data from 409 patients with HCC who stopped taking sorafenib between September 2008 and February 2015 were reviewed. Results In the training cohort, four factors were independent negative predictors of survival (p<0.05). Based on the β regression… CONTINUE READING